Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Metronomic Decitabine-Cedazuridine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia R/R AML), High Risk Myelodysplastic Syndrome (HR-MDS), and High-Risk Myeloproliferative Neoplasms (HR/AP MPN)

NCT07710534 is registered in ClinicalTrials.gov with Virginia Commonwealth University as lead sponsor.

NCT NCT07710534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07710534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Metronomic Decitabine-Cedazuridine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia R/R AML), High Risk Myelodysplastic Syndrome (HR-MDS), and High-Risk Myeloproliferative Neoplasms (HR/AP MPN)
Lead sponsor
Virginia Commonwealth University
Phase
Phase 2
Overall status
Recruiting
Start date
September 16, 2026
Completion date
December 31, 2033
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high risk myelodysplastic syndrome, high risk myeloproliferative neoplasms, relapsed / refractory aml